Panitumumab: An Arrow on Target
- First Online:
- Cite this article as:
- Kopper, L. Pathol. Oncol. Res. (2010) 16: 143. doi:10.1007/s12253-010-9257-7
- 84 Downloads
Several options are available today in the treatment of advanced colorectal cancer: traditional chemotherapeutic regimens, targeted therapies, and their combinations. Panitumumab is a new, fully human anti-EGFR monoclonal antibody, what is well-tolerated, effective as a single agent in chemotherapy refractory patients and in different combinations. The clinical response is restricted to tumors with wild-type RAS, therefore the RAS status should be checked before treatment.